IndraLab

Statements

2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]-3-azetidinyl]acetonitrile inhibits ITCH. 3 / 3
| 3
reach
"At week 16, baricitinib 4-mg and 2-mg significantly reduced itch severity (Itch Numeric Rating Scale (NRS) (BREEZE-AD1: percent change from baseline -36.6% and -29.4% vs. placebo (-12.0%), p ≤.001 and p ≤.05; BREEZE-AD2: -47.2% and -46.9% vs. placebo (-16.6%), p ≤.001)."
33222559
reach
"Recent studies reported that baricitinib improved clinical signs and symptoms in patients with moderate-to-severe atopic dermatitis and induced rapid reduction of itch[32]."
| PMC
reach
"Recent studies reported that baricitinib improved clinical signs and symptoms in patients with moderate-to-severe atopic dermatitis and induced rapid reduction of itch XREF_BIBR."
| PMC